The cancer that launched the checkpoint inhibitor revolution–and where functional biomarkers are proving their predictive power.
Melanoma's unique biology made it the proving ground for checkpoint immunotherapy. High mutational burden generates abundant neoantigens, making melanoma cells visible to the immune system–if the checkpoints suppressing T cell activity can be released.
The success of checkpoint inhibitorsLoading... in melanoma validated the fundamental principle: the immune system can eliminate cancer when properly unleashed. This understanding now extends across oncology, but melanoma remains the paradigm.
Historic Change: Before immunotherapy, metastatic melanoma was nearly always fatal. Checkpoint inhibitors changed this—about 40% of patients now have durable long-term responses.
First Successes: Melanoma was where ipilimumab (anti-CTLA-4) first showed survival benefit, and where checkpoint inhibitor combinations were first proven superior.
Despite immunotherapy's success, patient selection remains imprecise. PD-L1 expression by IHC is used clinically but correlates poorly with response. Many PD-L1-negative patients respond; many PD-L1-positive patients do not.
This disconnect reflects a fundamental limitation: expression-based assaysLoading... report protein presence, not functional engagement. A tumor may express PD-L1 abundantly without that ligand actively suppressing T cells at immune synapses.
The Problem: 40% respond, but which 40%? PD-L1 expression testing helps but is imperfect—some "negative" patients respond, some "positive" don't.
The Need: Better biomarkers to identify likely responders upfront.
iFRETLoading... measurement of PD-1/PD-L1Loading... interaction in melanoma tissue directly quantifies checkpoint engagement at the molecular level. Early validation studies demonstrate that high checkpoint interaction correlates with immunotherapy response–the tumor is actively using this pathway for immune evasion, making it vulnerable to blockade.
Ongoing clinical collaborations, including the HAWK/OSU neoadjuvant oncolytic virus trial, are prospectively testing functional biomarker stratification in stage II melanoma.
The Evidence: In 176 melanoma patients, iFRET-measured PD-1/PD-L1 engagement predicted survival (P=0.05); expression did not (P=0.87).
Ongoing Research: Studies are investigating whether functional biomarkers can predict response to various immunotherapy approaches, including combinations and oncolytic viruses.
Clinical Evidence: Melanoma represents a key validation indication for QF-Pro. In 176 melanoma patients[3], iFRET-measured PD-1/PD-L1 interaction correlated with overall survival (P=0.05[3]), while PD-L1 expression showed no predictive value (P=0.87[3]).
In the neoadjuvant TVEC[8] study, complete responders showed significantly increased iFRET efficiency post-treatment compared to baseline, while non-responders showed unchanged values.
Click citation numbers to view full references in QF-Pro Applications & Clinical EvidenceLoading...
Melanoma evidence: In 176 patients, checkpoint interaction predicted survival while expression testing failed. In patients receiving TVEC therapy, responders showed increased checkpoint engagement after treatment–non-responders showed no change.
